Metal cobalt complex polymer and preparation method and application thereof

文档序号:1412157 发布日期:2020-03-10 浏览:11次 中文

阅读说明:本技术 金属钴络合的聚合物及其制备方法和应用 (Metal cobalt complex polymer and preparation method and application thereof ) 是由 邓伟侨 魏效农 张玲 李立 谢勇 高炜 姜磊 焦锋刚 于 2018-09-04 设计创作,主要内容包括:本申请公开了一种金属钴络合的聚合物,并且公开了所述聚合物的制备方法和应用。本申请所提供的聚合物可以在无溶剂无助催化剂的条件下催化二氧化碳与环状烷烃反应生成环状碳酸酯。本申请所提供的聚合物制备方法稳定可靠,步骤较短,有利于节约制备成本。本申请的聚合物作为催化剂时可以多次重复使用,且催化产率没有显著降低。(The application discloses a metal cobalt-complexed polymer, and discloses a preparation method and application of the polymer. The polymer provided by the application can catalyze the reaction of carbon dioxide and cyclic alkane to generate cyclic carbonate under the conditions of no solvent and no promoter. The polymer preparation method provided by the application is stable and reliable, has short steps, and is beneficial to saving the preparation cost. The polymer can be repeatedly used as a catalyst, and the catalytic yield is not obviously reduced.)

1. Metal cobalt complex polymer Co-CMP-A-N + R3R4R5L-, wherein the polymer has a structural unit according to formula I:

Figure FDA0001788704370000011

wherein A is selected from alkylene of C2-C10; l is-Selected from Cl-、Br-Or I-

X is selected from-CH2CH2-,-CH(CH2)4HC-or-C (CH)4C-;

R1Selected from-OAc, -Cl, -Br or-I;

R2selected from hydrogen, halogen elements, C1-C10 alkyl and-NO2And a group having a structural formula represented by formula (2):

Figure FDA0001788704370000012

wherein M is21,M22Independently selected from hydrogen, alkyl of C1-C5, aryl of C6-C18 and substituted aryl of C6-C18;

R3,R4,R5is n-butyl, n-propyl or ethyl, and R3,R4,R5The three groups may be the same or different.

L-is selected from Cl-, Br-or I-;

the polymerization degree of the polymer is 30-100.

2. The polymer of claim 1, wherein the polymer has a structural unit represented by formula I-1, a structural unit represented by formula I-2, a structural unit represented by formula I-3, a structural unit represented by formula I-4, a structural unit represented by formula I-5, a structural unit represented by formula I-6, or a structural unit represented by formula I-7:

Figure FDA0001788704370000021

Figure FDA0001788704370000031

Figure FDA0001788704370000041

3. a process for the preparation of a polymer according to claim 1 or 2, characterized in that it comprises at least the following steps:

a) the intermediate product I is prepared by the reaction of trihalophenol and dihaloalkane

The trihalophenol is at least one selected from compounds having the formula shown in formula II:

Figure FDA0001788704370000042

the dihaloalkane is selected from at least one of compounds having a chemical formula shown in formula III:

L4-A-L5 formula III

The intermediate product I is selected from at least one compound with a chemical formula shown in a formula IV:

Figure FDA0001788704370000043

wherein L is1、L2、L3、L4、L5Independently selected from Cl, Br or I; l is6Is L4And/or L5

b) Reacting the intermediate product I with trialkylsilylethylene to prepare an intermediate product II;

the trialkylsilyacetylene is selected from at least one compound with a chemical formula shown in a formula V:

wherein R is51、R52And R53Independently selected from C1-C4 straight or branched chain alkyl groups;

the intermediate product II has at least one of the compounds of the formula shown in formula VI:

Figure FDA0001788704370000051

c) reacting the intermediate product II with trialkylamine to prepare an intermediate product III;

the trialkylamine is at least one selected from compounds having the formula shown in formula VII:

Figure FDA0001788704370000052

the intermediate III is selected from at least one compound with a chemical formula shown as a formula VIII:

Figure FDA0001788704370000053

d) the intermediate product III and a cobalt-based salicylic acid complex Salen-Co-R1Reacting to obtain the target polymer Co-CMP-A-N + R3R4R5L-

The cobalt-based salicylic acid complex Salen-Co-R1 is selected from at least one compound having a chemical formula shown in formula IX:

Figure FDA0001788704370000054

preferably, the cobalt-based salicylic acid complex Salen-Co-R1The preparation process comprises the following steps:

1) 5-bromosalicylaldehyde compounds, diamine compounds and cobalt salt compounds react to prepare an intermediate IV (Salen-Co);

the diamine compound is one of ethylenediamine, 1, 2-cyclohexanediamine or o-phenylenediamine;

the cobalt salt compound is cobalt acetate or cobalt dichloride;

the 5-bromosalicylaldehyde compound is selected from at least one compound with the chemical formula shown in formula XII:

Figure FDA0001788704370000061

the intermediate IV is selected from at least one compound with a chemical formula shown in a formula XIII:

Figure FDA0001788704370000062

2) the intermediate IV (Salen-Co) and R1H reaction is carried out to obtain the cobalt-based salicylic acid complex Salen-Co-R1

The R is1H is selected from CH3COOH, HCl, HBr or HI;

preferably, the specific process of step a) includes dissolving the trihalophenol and the dihaloalkane in a solvent to form a mixed solution, adding a base to the mixed solution, and stirring to react under the protection of an inert gas to obtain an intermediate product I;

wherein the molar ratio of the trihalophenol, the dihaloalkane and the base is 1: (3-5): (5-6).

4. The synthesis method according to claim 3, wherein the solvent is anhydrous acetone, and the base is selected from anhydrous K2CO3Anhydrous Na2CO3Or anhydrous NaHCO3The stirring reaction is carried out at the temperature of 50-70 ℃, and the stirring reaction time is 48-60 h.

5. The synthesis method according to claim 3, wherein the specific process of the step b) comprises dissolving the intermediate product I and the trialkylsilyacetylene in a solvent to form a mixed solution, adding a catalyst into the mixed solution, stirring and reacting under the protection of an inert gas, and then adding an alkali to remove the silylyne group to obtain an intermediate product II;

wherein the molar ratio of the intermediate product I to the trialkylsilyacetylene is 1: (3-4), wherein the molar ratio of the alkali to the intermediate product I is (1-1.5): 4;

preferably, the solvent is dry triethylamine and the catalyst is Pd (PPh)3)2Cl2And CuI, the base being selected from anhydrous K2CO3Anhydrous Na2CO3The stirring reaction is carried out at the temperature of 60-80 ℃, the stirring reaction time is 24-36 h, preferably, the catalyst is used in an amount such that the molar ratio of CuI to intermediate product I is 1: (3-5) Pd (PPh)3)2Cl2And intermediate I in a molar ratio of 1: (10-15).

6. The synthesis method of claim 3, wherein the specific process of step c) comprises dissolving the intermediate product II and trialkylamine in a solvent to form a mixed solution, and stirring the mixed solution under protection of inert gas and protection from light to react;

wherein the molar ratio of the intermediate compound II to the trialkylamine is 2: (3-5).

Preferably, the solvent is chloroform and acetonitrile in a volume ratio of 1: 1, the stirring reaction is carried out at the temperature of 60-80 ℃, and the stirring reaction time is 72-96 h.

7. The synthesis method according to claim 3, wherein the specific process of step d) comprises reacting the intermediate III with the cobalt-based salicylic acid complex Salen-Co-R1Dissolving the mixture in cA solvent to form cA mixed solution, and stirring the mixed solution to react in the presence of cA catalyst to obtain cA target polymer Co-CMP-A-N + R3R4R5L-;

Wherein the molar ratio of the intermediate product III to the cobalt-based salicylic acid complex Salen-Co-R1 is (2-4): 1;

preferably, the catalyst is Pd (PPh)3)4And CuI, wherein the dosage of the catalyst is satisfied, and the molar ratio of the CuI to the intermediate product III is 1: (5 to 10) Pd (PPh)3)4The molar ratio to intermediate III was 1: (20-30);

preferably, the solvent is anhydrous toluene and dry triethylamine in a volume ratio of 3: 1, the stirring reaction is carried out at 40-90 ℃, and the stirring reaction time is 60-90 hours.

8. Use of a polymer according to claim 1 or 2 or a polymer prepared using a method according to any one of claims 3 to 7, wherein the polymer is used to catalyse the reaction of carbon dioxide with an alkylene oxide to form a cyclic carbonate.

9. The use according to claim 8, wherein the polymer catalyzes the reaction of carbon dioxide with alkylene oxide to form cyclic carbonate by the following steps:

mixing the polymer and the alkylene oxide at a mass ratio of 1: (10-50) feeding, wherein the pressure of carbon dioxide is 0.1-6.0 MPa, and the temperature is 25-120 ℃ and stirring reaction is carried out for 1-72 h to obtain the corresponding cyclic carbonate.

10. Use according to claim 9, characterized in that the cycloalkanes are chosen from ethylene oxide, propylene oxide, epichlorohydrin, 1, 2-butylene oxide, 1, 2-cyclohexene oxide, phenyl ethylene oxide, propylene oxide, cyclohexene oxide, 1, 2-dodecane oxide, 1, 2-epoxy-5-hexene, 2, 3-epoxypropylpropargyl ether, 1,2,7, 8-diepoxyoctane, 1, 2-epoxy-2-methylpropane, trans-2, 3-butylene oxide, trans-1, 2-diphenylethylene oxide, 1-allyloxy-2, 3-propylene oxide, 1, 2-epoxy-3-phenoxypropane, 2-fluoroethylene oxide, 2, 2-difluoroethylene oxide or 1,1, 1-trifluoro-2, 3-propylene oxide.

Technical Field

The application relates to a metal cobalt complex polymer and a preparation method and application thereof, belonging to the field of organic chemistry.

Background

CO2Gases are the most prominent greenhouse gases in human activities. With the increasing severity of the greenhouse effect, people pay more and more attention to the treatment and absorption of carbon dioxide. Reduction of CO in the atmosphere at present2There are two main categories of methods: adsorption capture and catalytic conversion. Namely, the organic matter is converted by fixing or adopting a chemical catalytic conversion method, and the high-efficiency implementation of the processes has great significance for the healthy development of the human society. In the field of chemical catalytic conversion, using CO2The synthesis of cyclic carbonates by cycloaddition with cyclic alkanes is one of the most important routes, by which CO is introduced2To organic chemicals of higher commercial utility.

Ethylene Carbonate (EC), also known as 1, 3-dioxolanone or Ethylene Carbonate, is a superior organic high boiling point solvent and an intermediate for organic chemical synthesis, as well as other cyclic carbonates, is a basic raw material in organic chemical industry, and is widely used in the fields of printing and dyeing, textiles, electrochemistry, polymer synthesis, and the like. In recent years, research shows that ethylene carbonate can be used for high-energy battery electrolyte with high added value, and synthesis of dimethyl carbonate (DMC) and Ethylene Glycol (EG). More researches show that 3,3,3-trifluoro propylene carbonate (TFPC for short) can replace linear carbonate to obtain better discharge capacity and cycle life, and can greatly improve the safety, voltage resistance and charging cycle performance of the battery. These show the application prospects of cyclic carbonates and the strong demand of the market for them. Ethylene oxide and derivatives thereof and carbon dioxide in the presence of a catalystCan generate corresponding cyclic carbonate under the action, is beneficial to solving CO2The pollution problem caused by gas emission can supplement the demand of the market for the cyclic carbonate. It is worth noting that most of the currently reported reaction methods require relatively harsh reaction conditions such as high temperature and high pressure (155-200 ℃, 6-9 MPa) and long reaction time, so that industrial production is difficult to carry out, and ethylene oxide is gas at normal temperature and is easy to polymerize, so that a class of reaction methods capable of realizing CO under relatively mild conditions is sought2The high-efficiency catalyst for catalytic conversion is a problem to be solved urgently at present.

Disclosure of Invention

According to one aspect of the present application there is provided a metallic cobalt complexed polymer having structural units according to formula I:

Figure BDA0001788704380000011

wherein A is selected from C2~C10An alkylene group of (a); l is-Selected from Cl-、Br-Or I-

X is selected from-CH2CH2-,-CH(CH2)4HC-or-C (CH)4C-;

R1Selected from-OAc, -Cl, -Br or-I;

R2selected from hydrogen, halogen elements, C1~C10Alkyl of-NO2And a group having a structural formula represented by formula (1):

Figure BDA0001788704380000021

wherein M is11,M22Independently selected from hydrogen, C1~C5Alkyl of (C)6~C18Aryl of (C)6~C18Substituted aryl of (a);

R3,R4,R5is n-butyl, n-propyl or ethyl, and R3,R4,R5The three groups may be the same or different.

The polymerization degree of the polymer is 30-100.

Preferably, R1Any one selected from the group consisting of-OAc, -Cl, -Br and-I.

Preferably, R2Selected from the group consisting of-H, -tBu, -iBu, -NO2,-Cl,-CH2NEt2and-CH2N(Bn)Et2Any one of Br.

Preferably, R3、R4、R5Are the same group. Further preferably, R3、R4、R5Are all n-butyl.

Preferably, the polymer has a structural unit shown as a formula I-1, a structural unit shown as a formula I-2, a structural unit shown as a formula I-3, a structural unit shown as a formula I-4, a structural unit shown as a formula I-5, a structural unit shown as a formula I-6 or a structural unit shown as a formula I-7:

Figure BDA0001788704380000022

Figure BDA0001788704380000031

Figure BDA0001788704380000041

according to another aspect of the present application, a process for the preparation of said polymer is provided, comprising at least the following steps:

a) the intermediate product I is prepared by the reaction of trihalophenol and dihaloalkane

The trihalophenol is at least one selected from compounds having the formula shown in formula II:

Figure BDA0001788704380000042

the dihaloalkane is selected from at least one of compounds having a chemical formula shown in formula III:

L4-A-L5formula III

The intermediate product I is selected from at least one compound with a chemical formula shown in a formula IV:

Figure BDA0001788704380000043

L1、L2、L3、L4、L5independently selected from Cl, Br or I; l is6Is L4And/or L5

b) Reacting the intermediate product I with trialkylsilylethylene to prepare an intermediate product II;

the trialkylsilyacetylene is selected from at least one compound with a chemical formula shown in a formula V:

Figure BDA0001788704380000051

wherein R is51、R52And R53Independently selected from C1-C4 straight or branched chain alkyl groups;

the intermediate product II has at least one of the compounds of the formula shown in formula VI:

c) reacting the intermediate product II with trialkylamine to prepare an intermediate product III;

the trialkylamine is at least one selected from compounds having the formula shown in formula VII:

Figure BDA0001788704380000053

the intermediate III is selected from at least one compound with a chemical formula shown as a formula VIII:

Figure BDA0001788704380000054

d) the intermediate product III and a cobalt-based salicylic acid complex Salen-Co-R1Reacting to obtain the polymer Co-CMP-A-N+R3R4R5L-

The cobalt-based salicylic acid complex Salen-Co-R1At least one selected from compounds having the formula shown in formula IX:

Figure BDA0001788704380000055

preferably, the cobalt-based salicylic acid complex Salen-Co-R1The preparation process comprises the following steps:

1) reacting the 5-bromosalicylaldehyde compound with a diamine compound and a cobalt salt to obtain an intermediate IV;

the diamine compound is selected from one of ethylenediamine, 1, 2-cyclohexanediamine or o-phenylenediamine;

the cobalt salt compound is selected from Co (OAc)2And CoCl2One of (1);

the 5-bromosalicylaldehyde compound is selected from at least one compound with the chemical formula shown in formula XII:

the intermediate IV is selected from at least one compound with a chemical formula shown in a formula XIII:

2) the intermediates IV and R1H reaction is carried out to obtain the cobalt-based salicylic acid complex Salen-Co-R1

The R is1H is CH3COOH, HCl, HBr or HI.

Preferably, the specific process of step a) includes dissolving the trihalophenol and the dihaloalkane in a solvent to form a mixed solution, adding a base to the mixed solution, and stirring under the protection of an inert gas to react to obtain an intermediate product I,

wherein the molar ratio of the trihalophenol, the dihaloalkane and the base is 1: (3-5): (5-6).

Preferably, the solvent is dry acetone, the base is one or more of anhydrous potassium carbonate, anhydrous sodium carbonate and anhydrous sodium bicarbonate, the stirring reaction is carried out at 50-70 ℃, and the stirring reaction time is 48-60 h.

Preferably, the specific process of step b) includes dissolving the intermediate product I and the trialkylsilyacetylene in a solvent to form a mixed solution, adding a catalyst into the mixed solution, stirring for reaction under the protection of an inert gas, adding an alkali to remove the silylynyl group to obtain an intermediate product II,

wherein the molar ratio of the intermediate product I to the trialkylsilyacetylene is 1: (3-4), wherein the molar ratio of the alkali to the intermediate product I is (1-1.5): 4.

preferably, the solvent is dry triethylamine and the catalyst is Pd (PPh)3)2Cl2And CuI, wherein the alkali is one or more of anhydrous potassium carbonate and anhydrous sodium carbonate, the stirring reaction is carried out at the temperature of 60-80 ℃, the stirring reaction time is 24-36 h, preferably, the catalyst is used in an amount meeting the requirement that the molar ratio of the CuI to the intermediate product I is 1: (3-5) Pd (PPh)3)2Cl2And intermediate I in a molar ratio of 1: (10-15).

Preferably, the specific process of step c) includes dissolving the intermediate product II and trialkylamine in a solvent to form a mixed solution, and stirring and reacting under protection of inert gas and in the dark to obtain an intermediate product III;

wherein the molar ratio of the intermediate product II compound to the trialkylamine is 2: (3-4).

Preferably, the solvent is chloroform and acetonitrile in a volume ratio of 1: 1, the stirring reaction is carried out at the temperature of 60-80 ℃, and the stirring reaction time is 72-96 h.

Preferably, the specific process of step d) comprises reacting said intermediate III with said cobalt-based salicylic acid complex Salen-Co-R1Dissolving the mixture in cA solvent to form cA mixed solution, and stirring the mixed solution to react in the presence of cA catalyst to obtain cA target polymer Co-CMP-A-N+R3R4R5L-

Wherein the intermediate product III and the cobalt-based salicylic acid complex Salen-Co-R1The molar ratio of (2-4): 1.

preferably, the catalyst is Pd (PPh)3)4And CuI, wherein the dosage of the catalyst is satisfied, and the molar ratio of the CuI to the intermediate product III is 1: (5 to 10) Pd (PPh)3)4And intermediate III in a molar ratio of 1: (20-30).

Preferably, the solvent is anhydrous toluene and anhydrous triethylamine in a volume ratio of 3: 1, the stirring reaction is carried out at 40-90 ℃, and the stirring reaction time is 60-90 hours.

According to another aspect of the present application, there is provided the use of the polymer or a polymer prepared using the method, wherein the polymer is used to catalyse the reaction of carbon dioxide with an alkylene oxide to cyclic carbonate.

Preferably, the polymer catalyzes a reaction of carbon dioxide and alkylene oxide to form a cyclic carbonate, and the method comprises:

mixing the catalyst and alkylene oxide according to the mass ratio of 1: (10-50) feeding, wherein the pressure of carbon dioxide is 0.1-6.0 MPa, and the temperature is 25-120 ℃ and stirring reaction is carried out for 1-48 h to obtain the corresponding cyclic carbonate.

The ranges of the feeding ratios of the substances mentioned in the invention, including the mass ratio, the volume ratio and the molar ratio, all include any point or range within the range of the ratio.

Catalysis of alkylene oxides with CO with said catalysts2The reaction formula (c) is as follows:

Figure BDA0001788704380000071

the reaction process in the formula does not need to add any solvent or cocatalyst; the molar ratio of the alkylene oxide to the catalyst provided by the invention is about (100-2000): 1; in the formula R6=-H、-CH3、-CH2CH3、-CH2CH2Cl、-CH2CH2CH2CH3、-Ph、-CH2Ph, -F or-CF3And so on.

In this application, C2~C10、C1~C5、C6~C18And the like refer to the number of carbon atoms involved. Such as "C1~C5The "alkyl group" refers to an alkyl group having 1 to 5 carbon atoms.

In the present application, an "alkylene group" is a group formed by losing any two hydrogen atoms on the molecule of an alkane compound. An "alkyl" group is a group formed by the loss of any one hydrogen atom from the molecule of an alkane compound. The alkane compound comprises straight-chain alkane, branched-chain alkane, cycloalkane and cycloalkane with branched chain.

In the present application, "aryl" is a group formed by losing one hydrogen atom on an aromatic ring on an aromatic compound molecule; such as p-tolyl, formed by toluene losing the hydrogen atom para to the methyl group on the phenyl ring.

In the present application, the "halogen" refers to at least one of fluorine, chlorine, bromine and iodine.

As used herein, the term "substituted aryl" refers to an aryl group wherein at least one hydrogen atom is replaced with a substituent selected from the group consisting of halogen, -NO2And a group having a structural formula represented by formula (2).

The beneficial effects that this application can produce include:

1) the catalyst provided by the application can catalyze the reaction of carbon dioxide and cyclic alkane to generate cyclic carbonate under the condition of no solvent or cocatalyst.

2) The preparation method of the catalyst provided by the application is stable and reliable, has short steps, and is beneficial to saving the preparation cost.

3) The catalyst of the present application can be reused many times.

Drawings

FIG. 1 shows 1,3, 5-tribromo-2- [ (4-bromobutyl) oxy]Process for preparation of benzene1H NMR;

FIG. 2 shows 1,3, 5-tribromo-2- [ (4-bromobutyl) oxy]Process for preparation of benzene13C NMR;

FIG. 3 shows 2- [ (4-bromobutyl) oxy]Of-1, 3, 5-triethynylbenzenes1H NMR;

FIG. 4 shows 2- [ (4-bromobutyl) oxy]Of-1, 3, 5-triethynylbenzenes13C NMR;

FIG. 5 is a drawing of N, N, N-tributyl-4- (2,4, 6-triethynylphenoxy) butane-1-aminylbromide1H NMR;

FIG. 6 is a drawing of N, N, N-tributyl-4- (2,4, 6-triethynylphenoxy) butane-1-aminylbromide13C NMR;

FIG. 7 is an FT-IR of a catalyst monomer molecule herein;

FIG. 8 shows 1,3, 5-tribromo-2- [ (6-bromohexyl) oxy]Process for preparation of benzene1H NMR;

FIG. 9 shows 1,3, 5-tribromo-2- [ (6-bromohexyl) oxy]Process for preparation of benzene13C NMR;

FIG. 10 shows 2- [ (6-bromohexyl) oxy]Of-1, 3, 5-triethynylbenzenes1H NMR;

FIG. 11 shows 2- [ (6-bromohexyl) oxy]Of-1, 3, 5-triethynylbenzenes13C NMR;

FIG. 12 is a drawing of N, N, N-tributyl-6- (2,4, 6-triethynylphenoxy) hexane-1-aminylbromide1H NMR;

FIG. 13 is a drawing of N, N, N-tributyl-6- (2,4, 6-triethynylphenoxy) hexane-1-aminylbromide13C NMR;

FIG. 14 is an FT-IR of a catalyst monomer molecule herein;

FIG. 15 is an FT-IR of a catalyst monomer molecule herein;

FIG. 16 shows 1,3, 5-tribromo-2- [ (8-bromooctyl) oxy group]Process for preparation of benzene1H NMR;

FIG. 17 shows 1,3, 5-tribromo-2- [ (8-bromooctyl) oxy group]Process for preparation of benzene13C NMR;

FIG. 18 shows 2- [ (8-bromooctyl) oxy group]Of-1, 3, 5-triethynylbenzenes1H NMR;

FIG. 19 is 2- [ (8-bromooctyl) oxy group]Of-1, 3, 5-triethynylbenzenes13C NMR;

FIG. 20 is a drawing showing the preparation of N, N, N-tributyl-8- (2,4, 6-triethynylphenoxy) octane-1-aminylbromide1H NMR;

FIG. 21 is a drawing showing the preparation of N, N, N-tributyl-8- (2,4, 6-triethynylphenoxy) octane-1-aminylbromide13C NMR;

FIG. 22 is an FT-IR of a catalyst monomer molecule herein;

FIG. 23 is H-NMR of propylene carbonate;

FIG. 24 is C-NMR of propylene carbonate;

FIG. 25 is H-NMR of ethylene carbonate;

FIG. 26 is C-NMR of ethylene carbonate;

FIG. 27 is H-NMR of 4-chloro-1, 3-dioxolane-2-one;

FIG. 28 is a C-NMR of 4-chloro-1, 3-dioxolane-2-one;

FIG. 29 is H-NMR of 4-ethyl-1, 3-dioxolane-2-one;

FIG. 30 is a C-NMR of 4-ethyl-1, 3-dioxolane-2-one;

FIG. 31 is the H-NMR of 4-butyl-1, 3-dioxolane-2-one;

FIG. 32 is C-NMR of 4-butyl-1, 3-dioxolane-2-one;

FIG. 33 is a H-NMR of 4-fluoro-1, 3-dioxolan-2-one;

FIG. 34 is a C-NMR of 4-fluoro-1, 3-dioxolan-2-one;

FIG. 35 is H-NMR of 4-phenyl-1, 3-dioxolane-2-one;

FIG. 36 is a C-NMR of 4-phenyl-1, 3-dioxolane-2-one;

FIG. 37 is H-NMR of 4-trifluoromethyl-1, 3-dioxolan-2-one;

FIG. 38 is a C-NMR of 4-trifluoromethyl-1, 3-dioxolan-2-one.

Detailed Description

The present application will be described in detail with reference to examples, but the present application is not limited to these examples.

Unless otherwise specified, the raw materials and catalysts in the examples of the present application were all purchased commercially.

In the following examples, the structure shown by formula XI (hereinafter abbreviated as Salen-Co-R)1) The compound is prepared by adopting a synthesis method in Chinese patent CN 103381370B.

The analysis method in the examples of the present application is as follows:

1HNMR and13c NMR was measured using a BRUKER MERCURY-PLUS 400-MHz type spectrometer instrument.

FT-IR was measured using an Agilent Cary630 Fourier transform Infrared Spectroscopy instrument.

53页详细技术资料下载
上一篇:一种医用注射器针头装配设备
下一篇:随机共轭共聚物、其制备方法和其在有机光电元件上的应用

网友询问留言

已有0条留言

还没有人留言评论。精彩留言会获得点赞!

精彩留言,会给你点赞!